Cervical cancer vaccine shows 100% efficacy during clinical trial in China  A recent study has found that China’s first self-developed HPV vaccine, Cecolin, can offer female adults full immunity against HPV 16 and 18, two major Human Papillomavirus (HPV) types causing 70 percent of all cervical cancers. Cecolin HPV vaccine was jointly developed by Innovax, a biotechnology company based in Xiamen, Fujian province, China, in cooperation with Xiamen University. A group of Chinese researchers analysed data from 66-month follow-up visits as part of the bivalent vaccine’s Phase 3 clinical trial. They found that its...